Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • TYK2 Inhibitor
Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial
Posted inClinical Updates news

Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial

Posted by MedXY By MedXY 01/27/2026
This review synthesizes findings from a Phase 2 trial of ICP-332, a novel TYK2 inhibitor, demonstrating significant EASI score improvements and a manageable safety profile in moderate to severe atopic dermatitis.
Read More
  • Minor Papillotomy for Pancreas Divisum: The SHARP Trial Challenges Decades of Endoscopic Practice
  • Group Therapy for Prolonged Grief in Older Adults Proves Noninferior to Individual CBT
  • Selective TYK2 Inhibition in Atopic Dermatitis: Efficacy and Safety of ICP-332 in a Phase 2 Randomized Clinical Trial
  • Activating EGFR L858R Variants Linked to Syndromic Generalized Acanthosis Nigricans and Pulmonary Risk: A New Clinical Entity
  • PTSD and Sleep Disorders Linked to Sharp Rise in Acute Coronary Syndrome Risk
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality nutrition obesity older adults oncology Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in